Every 10-Q that Mosaic Immunoengineering Inc (CPMV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CPMV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPMV filings page.
Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on cancer immunotherapies and reported another pre-revenue quarter for the three and six months ended June 30, 2026. The company recorded a net loss of $177,496 for the quarter and $352,847 year-to-date, driven by modest research and development expenses of about $31,000 and general and administrative expenses of about $280,000 for the six-month period. Interest expense on existing convertible notes and a $200,000 unsecured convertible note totaled about $41,000 for the six months.
Liquidity is extremely constrained: cash and cash equivalents were $26 at June 30, 2026, while total liabilities were $7,832,145 against total assets of $3,278, resulting in a stockholders’ deficit of $(7,828,867). Management states that existing cash will not fund operations for 12 months and that these conditions raise substantial doubt about the company’s ability to continue as a going concern. The company remains dependent on raising additional capital through equity, debt, or strategic transactions, with no arrangements currently in place. A prior binding term sheet with Oncotelic Therapeutics to acquire oncology and AI assets expired on June 30, 2025, and key license agreements with Case Western Reserve University and one UC San Diego program have been terminated, while related patent and license fees remain accrued.
Mosaic ImmunoEngineering, Inc. reported Q1 2026 results that highlight its early-stage status and severe funding constraints. The company generated no revenue and recorded a net loss of $175,351, slightly improved from $181,320 a year earlier, driven by research and development expenses of about $16,000 and general and administrative costs of about $139,000.
Cash and cash equivalents fell to just $72 at March 31, 2026, down from $3,622 at year-end 2025, while total liabilities were $7.66M and stockholders’ deficit was $7.65M. Management states there is substantial doubt about the company’s ability to continue as a going concern and notes there are no current financing arrangements in place.
The company relies on $1.48M of convertible notes and a $200,000 unsecured convertible note for funding, and it has accrued significant obligations, including $406,973 of patent fees under a terminated license and $264,375 of related-party consulting fees. A previously announced $15.0M strategic transaction term sheet with Oncotelic expired without a definitive agreement, leaving Mosaic still searching for new product candidates and capital.
Mosaic ImmunoEngineering, Inc. reported a Q3 2025 net loss of $165,361, improving from a $186,730 loss a year earlier, as both research and development and general and administrative costs declined. For the first nine months of 2025, the company recorded a net loss of $518,709, versus $768,939 in the prior-year period, reflecting lower payroll and operating expenses.
Cash and cash equivalents were only $31,761 as of September 30, 2025, against total liabilities of $7,362,181 and a stockholders’ deficit of $7,306,883, and management states there is substantial doubt about the company’s ability to continue as a going concern without new capital. Mosaic remains a development-stage oncology-focused biotech, has not generated revenue, and is relying on future financings while its previous $15.0 million asset acquisition term sheet with Oncotelic has expired. As of November 19, 2025, 7,242,137 common shares were outstanding.